z-logo
open-access-imgOpen Access
Synthesis of 4′-Ethynyl-2′-deoxy-4′-thioribonucleosides and Discovery of a Highly Potent and Less Toxic NRTI
Author(s) -
Kazuhiro Haraguchi,
Hisashi Shimada,
Keiogo Kimura,
Genta Akutsu,
Hiromichi Tanaka,
Hiroshi Abe,
Takayuki Hamasaki,
Masanori Baba,
Elizabeth A. Gullen,
Ginger E. Dutschman,
YungChi Cheng,
Jan Balzarini
Publication year - 2011
Publication title -
acs medicinal chemistry letters
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.065
H-Index - 66
ISSN - 1948-5875
DOI - 10.1021/ml2001054
Subject(s) - chemistry , glycal , electrophile , nucleobase , stereochemistry , deoxyadenosine , deoxyguanosine , glycosyl , cytosine , combinatorial chemistry , dna , organic chemistry , stereoselectivity , biochemistry , catalysis
The synthesis of 4'-ethynyl-2'-deoxy-4'-thioribonucleosides was carried out utilizing an electrophilic glycosidation in which 4-ethynyl-4-thiofuranoid glycal 16 served as a glycosyl donor. Electrophilic glycosidation between 16 and the silylated nucleobases ( N 4 -acetylcytosine, N 6 -benzoyladenine and N 2 -acetyl- O 6 -diphenylcarbamoylguanine) was carried out in the presence of N -iodosuccinimide (NIS) leading to the exclusive formation of the desired β-anomers 29, 33 and 36 . Anti-HIV studies demonstrated that these 4'-thio nucleosides were less cytotoxic to T-lymphocyte (i.e. MT-4 cells) than the corresponding 4'-ethynyl derivatives of 2'-deoxycytidine ( 44 ), 2'-deoxyadenosine ( 45 ) and 2'-deoxyguanosine ( 46 ). Comparison of the selectivity indices (SI) was made between 4'-thionucleosides ( 32, 41 and 43 ) and the corresponding 4'-oxygen analogues 44-46 by using the reported CC 50 and EC 50 values. In the case of cytosine and adenine nucleosides, comparable SI values were obtained: 32 (545) and 45 (458); 41 (>230) and 45 (1,630). In contrast, 4'-ethynyl-2'-deoxy-4'-thioguanosine 43 was found to possess a SI value of >18,200, which is twenty times better than that of 46 (933).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here